Loading clinical trials...
Loading clinical trials...
A Phase I/II Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
Conditions
Interventions
Mitoxantrone Hydrochloride Liposome
Locations
1
China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
June 14, 2022
Primary Completion Date
November 19, 2022
Completion Date
November 19, 2022
Last Updated
February 23, 2024
NCT06660368
NCT02074839
NCT05241093
NCT05241106
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions